Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of bleximenib + venetoclax + azacitidine in newly diagnosed intensive chemotherapy-ineligible AML with KMT2A rearrangement or NPM1 mutation
CTR20252211Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bleximenib in acute myeloid leukemia (AML), sponsored by Janssen Pharmaceutical. Started Jul 2025; status: active.
02
Drugs
bleximenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20252211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252211.